|
|
News Breaks | | | | August 3, 2012 | | 15:22 EDT |  | REGN, SNY | Regeneron and Sanofi confirm FDA approval of Zaltrap
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) confirmed that the U.S. Food and Drug Administration approved ZALTRAP Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan, for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. Sanofi plans to make ZALTRAP available in the U.S. in the third quarter of 2012. Under the terms of their collaboration agreement, Sanofi and Regeneron share equally the global profits of ZALTRAP after Regeneron's obligation to repay its share of development expenses. In the U.S., ZALTRAP is a registered trademark of Regeneron Pharmaceuticals. | |
|
News For REGN;SNY From The Last 14 Days Check below for free stories on REGN;SNY the last two weeks. |
|
|
| June 18, 2013 | | 11:52 EDT |  | REGN | Stocks with call strike movement; REGN MU
 Subscribe for More Information | | | 08:38 EDT |  | SNY | Sanofi management to meet with JPMorgan
Subscribe for More Information | | | 08:36 EDT |  | REGN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. | | | June 13, 2013 | | 11:02 EDT | | SNY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | June 10, 2013 | | 07:20 EDT | | SNY | Biomed to host a conference
Subscribe for More Information | | | 07:03 EDT | | SNY | Sanofi announces FDA approved sBLA for licensure of influenza vaccine
Subscribe for More Information | | | June 6, 2013 | | 05:49 EDT | | REGN | Regeneron, Bayer reports positive Phase 3 results for Eylea
Regeneron Pharmaceuticals (REGN) and Bayer HealthCare (BAYRY) announced positive top-line results for EYLEA Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization. In this trial, patients receiving EYLEA at an initial dose of 2 milligrams, followed by treatment on an as-needed basis, had a mean improvement in best-corrected visual acuity from baseline at week 24 of 12.1 letters, compared to a loss of 2.0 letters in patients receiving sham injections. The most common adverse events observed in the MYRROR trial that occurred with a frequency of 2% or more were conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis. | |
|
|
|
|
|
|
